Patents Assigned to Royal Holloway and Bedford New College
-
Patent number: 11725032Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding a functional dystrophin protein. Also described is a vector, a host cell and a pharmaceutical composition comprising the nucleic acid molecule; use of the nucleic acid molecule in therapy, such as in the treatment of a muscular dystrophy; and a method of treating muscular dystrophy, the method comprising administering a therapeutically effective amount of the nucleic acid molecule to a patient suffering from a muscular dystrophy.Type: GrantFiled: December 5, 2018Date of Patent: August 15, 2023Assignee: Royal Holloway And Bedford New CollegeInventors: George Dickson, Linda Popplewell
-
Patent number: 10947536Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.Type: GrantFiled: April 20, 2020Date of Patent: March 16, 2021Assignee: Royal Holloway and Bedford New CollegeInventors: John George Dickson, Jagjeet Kaur Kang
-
Patent number: 10859641Abstract: A quantum interference device includes a superconducting loop interrupted by a normal conductor segment, and an interferometer connected to the normal conductor segment, wherein the superconducting loop includes a plurality of turns. The turns can be a plurality of adjacent lobes. A coil can be located within a lobe of the superconducting loop. Optionally, a bridge layer (e.g., of gold) is formed above the substrate to make an electrical contact between a superconducting layer (e.g., of niobium) formed above the bridge layer and a normal conducting layer (e.g., of titanium) formed above the bridge layer. The bridge layer allows the device to be formed of superconducting and normal conducting material that are otherwise incompatible. A titanium normal conducting layer can be allowed to oxidize over a period of years.Type: GrantFiled: August 26, 2016Date of Patent: December 8, 2020Assignee: Royal Holloway and Bedford New CollegeInventors: Victor Tikhonovich Petrashov, Christopher Checkley
-
Patent number: 10786546Abstract: A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein: the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin; the composition is systemically administered.Type: GrantFiled: November 9, 2018Date of Patent: September 29, 2020Assignees: GENETHON, ROYAL HOLLOWAY AND BEDFORD NEW COLLEGEInventors: George Dickson, Thomas Voit, Philippe Moullier, Caroline Le Guiner
-
Patent number: 10662431Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.Type: GrantFiled: August 13, 2019Date of Patent: May 26, 2020Assignee: ROYAL HOLLOWAY AND BEDFORD NEW COLLEGEInventors: John George Dickson, Jagjeet Kaur Kang
-
Patent number: 10647751Abstract: An adeno-associated viral (AAV) vector containing an expression construct, wherein: the expression construct comprises a nucleic acid sequence which encodes a microdystrophin (MD); and the nucleic acid sequence encoding the MD has a size of at least 4.1 kb.Type: GrantFiled: May 9, 2016Date of Patent: May 12, 2020Assignee: ROYAL HOLLOWAY & BEDFORD NEW COLLEGEInventor: George Dickson
-
Patent number: 10421969Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.Type: GrantFiled: September 12, 2018Date of Patent: September 24, 2019Assignee: Royal Holloway and Bedford New CollegeInventors: John George Dickson, Jagjeet Kaur Kang
-
Patent number: 10301263Abstract: The invention relates to pharmaceutical uses of compounds of formula (II). Particular aspects of the invention relate to the use of those compounds in treating, preventing or ameliorating a seizure-related disorder, bipolar disorder, mania, migraine, Alzheimer's disease, Parkinson's disease or stroke.Type: GrantFiled: September 10, 2015Date of Patent: May 28, 2019Assignee: Royal Holloway and Bedford New CollegeInventors: Robin Williams, Matthew Walker
-
Patent number: 10166272Abstract: A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein: —the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin; —the composition is systemically administered.Type: GrantFiled: April 24, 2015Date of Patent: January 1, 2019Assignees: GENETHON, ROYAL HOLLOWAY AND BEDFORD NEW COLLEGEInventors: George Dickson, Thomas Voit, Philippe Moullier, Caroline Le Guiner
-
Publication number: 20180346533Abstract: An adeno-associated viral (AAV) vector containing an expression construct, wherein: the expression construct comprises a nucleic acid sequence which encodes a microdystrophin (MD); and the nucleic acid sequence encoding the MD has a size of at least 4.1 kb.Type: ApplicationFiled: May 9, 2016Publication date: December 6, 2018Applicant: ROYAL HOLLOWAY & BEDFORD NEW COLLEGEInventor: George Dickson
-
Patent number: 10106795Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.Type: GrantFiled: March 23, 2016Date of Patent: October 23, 2018Assignee: Royal Holloway and Bedford New CollegeInventors: John George Dickson, Jagjeet Kaur Kang
-
Publication number: 20170305859Abstract: The invention relates to pharmaceutical uses of compounds of formula (II). Particular aspects of the invention relate to the use of those compounds in treating, preventing or ameliorating a seizure-related disorder, bipolar disorder, mania, migraine, Alzheimer's disease, Parkinson's disease or stroke.Type: ApplicationFiled: September 10, 2015Publication date: October 26, 2017Applicant: Royal Holloway and Bedford New CollegeInventors: Robin WILLIAMS, Matthew WALKER
-
Publication number: 20170022502Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy.Type: ApplicationFiled: March 23, 2016Publication date: January 26, 2017Applicant: Royal Holloway And Bedford New CollegeInventors: John George Dickson, Jagjeet Kaur Kang
-
Patent number: 9322019Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.Type: GrantFiled: October 2, 2014Date of Patent: April 26, 2016Assignee: Royal Holloway and Bedford New CollegeInventors: John George Dickson, Jagjeet Kaur Kang
-
Publication number: 20150343049Abstract: The invention relates to vaccines, and particularly to vaccines active against pathogenic bacteria including Clostridia species, such as C. difficile, and Bacillus species, such as B. anthracis and B. cereus. The invention is concerned with the use of nucleic acids and proteins as antigens for use in vaccine design and construction, and to the vaccines per se. The nucleic acids and proteins are also useful in diagnostic test kits and methods for the detection of Clostridium spp. and Bacillus spp. infections.Type: ApplicationFiled: April 14, 2015Publication date: December 3, 2015Applicant: Royal Holloway and Bedford New College, University of LondonInventor: Simon Michael Cutting
-
Patent number: 9139625Abstract: The invention provides novel surface coat proteins of Clostridium spp. spores, and nucleic acids encoding such proteins. The invention extends to various uses of these nucleic acids and proteins, as antigens for use in vaccine design and construction, and to vaccines per se, and in diagnostic test kits and methods for the detection of Clostridium spp. infections. In addition, the nucleic acids and proteins can be used as potential targets for therapeutic drugs for the prevention or treatment of Clostridium spp. infections.Type: GrantFiled: May 10, 2012Date of Patent: September 22, 2015Assignee: Royal Holloway and Bedford New CollegeInventors: Simon Michael Cutting, Hong Anh Huynh
-
Publication number: 20140141031Abstract: The invention provides novel surface coat proteins of Clostridium spp. spores, and nucleic acids encoding such proteins. The invention extends to various uses of these nucleic acids and proteins, as antigens for use in vaccine design and construction, and to vaccines per se, and in diagnostic test kits and methods for the detection of Clostridium spp. infections. In addition, the nucleic acids and proteins can be used as potential targets for therapeutic drugs for the prevention or treatment of Clostridium spp. infections.Type: ApplicationFiled: May 10, 2012Publication date: May 22, 2014Applicant: ROYAL HOLLOWAY AND BEDFORD NEW COLLEGEInventors: Simon Michael Cutting, Hong Anh Huynh
-
Patent number: 8673311Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.Type: GrantFiled: September 21, 2010Date of Patent: March 18, 2014Assignee: Royal Holloway and Bedford New CollegeInventors: Simon Michael Cutting, Hong Anh Huynh
-
Publication number: 20140059089Abstract: There is provided a method of structuring a network of nodes, comprising: providing link information relating to existing links between the nodes (2); using the link information to partition the network into non-predetermined groups of related nodes (3), thereby forming a group structure for the network; identifying for each group a corpus of information associated with the nodes in that group (4); generating for each group a machine-readable characterisation of that group based on the corpus of information identified for the group (5); and structuring the network of nodes through the groups and their associated characterisations (2 to 7).Type: ApplicationFiled: December 16, 2011Publication date: February 27, 2014Applicant: ROYAL HOLLOWAY AND BEDFORD NEW COLLEGEInventor: John Alexander Bryden
-
Publication number: 20130085139Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy.Type: ApplicationFiled: October 4, 2012Publication date: April 4, 2013Applicant: ROYAL HOLLOWAY AND BEDFORD NEW COLLEGEInventor: Royal Holloway and Bedford New College